{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:56:31Z","timestamp":1760100991274},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University Medical Center Rotterdam (Erasmus MC)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00228-017-2283-6","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T05:13:12Z","timestamp":1499231592000},"page":"1271-1277","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population pharmacokinetics of haloperidol in terminally ill adult patients"],"prefix":"10.1007","volume":"73","author":[{"given":"L. G.","family":"Franken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A. A.","family":"Mathot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D.","family":"Masman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P. M.","family":"Baar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Tibboel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"issue":"3","key":"2283_CR1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1191\/0269216304pm879oa","volume":"18","author":"C Centeno","year":"2004","unstructured":"Centeno C, Sanz A, Bruera E (2004) Delirium in advanced cancer patients. Palliat Med 18(3):184\u2013194","journal-title":"Palliat Med"},{"issue":"2","key":"2283_CR2","first-page":"CD005594","volume":"18","author":"E Lonergan","year":"2007","unstructured":"Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev 18(2):CD005594","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2283_CR3","first-page":"89","volume":"8","author":"C Mazzocato","year":"2000","unstructured":"Mazzocato C, Stiefel F, Buclin T, Berney A (2000) Psychopharmacology in supportive care of cancer: a review for the clinician: II. Neuroleptics. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 8(2):89\u201397","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2283_CR4","unstructured":"Bannink M, de Graeff A, Monster H (2010) Integraal Kanker centrum Nederland. Deliria nation-wide guideline, version 3.0"},{"issue":"4","key":"2283_CR5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/clpt.1983.65","volume":"33","author":"FO Holley","year":"1983","unstructured":"Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE (1983) Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 33(4):477\u2013484","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2283_CR6","first-page":"20","volume":"46","author":"JR Magliozzi","year":"1985","unstructured":"Magliozzi JR, Hollister LE (1985) Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry 46(1):20\u201321","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2283_CR7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00216005","volume":"91","author":"YF Cheng","year":"1987","unstructured":"Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO et al (1987) Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology 91(4):410\u2013414","journal-title":"Psychopharmacology"},{"issue":"2","key":"2283_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00004714-198904000-00005","volume":"9","author":"KK Midha","year":"1989","unstructured":"Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL et al (1989) Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 9(2):98\u2013104","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2283_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00004714-199304000-00006","volume":"13","author":"V Khot","year":"1993","unstructured":"Khot V, DeVane CL, Korpi ER, Venable D, Bigelow LB, Wyatt RJ et al (1993) The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J Clin Psychopharmacol 13(2):120\u2013127","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2283_CR10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-200241020-00006","volume":"41","author":"E Yukawa","year":"2002","unstructured":"Yukawa E, Hokazono T, Yukawa M, Ichimaru R, Maki T, Matsunaga K et al (2002) Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet 41(2):153\u2013159","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2283_CR11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JCP.0b013e3182a4ee2c","volume":"33","author":"V Pilla Reddy","year":"2013","unstructured":"Pilla Reddy V, Kozielska M, Johnson M, Mafirakureva N, Vermeulen A, Liu J et al (2013) Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. J Clin Psychopharmacol 33(6):731\u2013739","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2283_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1049909111423094","volume":"29","author":"E Prommer","year":"2012","unstructured":"Prommer E (2012) Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Care 29(4):295\u2013301","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"2283_CR13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003088-197702010-00003","volume":"2","author":"TF Blaschke","year":"1977","unstructured":"Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2(1):32\u201344","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2283_CR14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/17425255.2016.1179281","volume":"12","author":"LG Franken","year":"2016","unstructured":"Franken LG, de Winter BC, van Esch HJ, van Zuylen L, Baar FP, Tibboel D et al (2016) Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opin Drug Metab Toxicol 12(6):669\u2013680","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7379","key":"2283_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/bmj.326.7379.30","volume":"326","author":"J Ellershaw","year":"2003","unstructured":"Ellershaw J, Ward C (2003) Care of the dying patient: the last hours or days of life. BMJ 326(7379):30\u201334","journal-title":"BMJ"},{"issue":"4","key":"2283_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00004714-198208000-00008","volume":"2","author":"CB Schaffer","year":"1982","unstructured":"Schaffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM (1982) Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 2(4):274\u2013277","journal-title":"J Clin Psychopharmacol"},{"key":"2283_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"2283_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90(2):154\u2013166","journal-title":"Comput Methods Prog Biomed"},{"issue":"4","key":"2283_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2283_CR20","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H et al (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2:e51","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"2283_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00561322","volume":"7","author":"WA Cressman","year":"1974","unstructured":"Cressman WA, Bianchine JR, Slotnick VB, Johnson PC, Plostnieks J (1974) Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 7(2):99\u2013103","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2283_CR22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1208\/s12248-013-9526-y","volume":"15","author":"AM Johansson","year":"2013","unstructured":"Johansson AM, Karlsson MO (2013) Comparison of methods for handling missing covariate data. AAPS J 15(4):1232\u20131241","journal-title":"AAPS J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2283-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T12:10:30Z","timestamp":1505391030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2283-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2283-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}